BIOTECHNOLOGY VALUE FUND L P - Dec 31, 2024 Form SCHEDULE 13G/A Schedule Report for Avalo Therapeutics, Inc. (AVTX)

Filing Manager
BIOTECHNOLOGY VALUE FUND L P
Reporting Manager
BVF PARTNERS L P/IL
Security
Avalo Therapeutics, Inc. Common Stock, $0.001 par value per share
Symbol
AVTX
Shares outstanding
10.4M shares
Disclosed Ownership
1.04M shares
Ownership
9.99%
Form type
SCHEDULE 13G/A
Date filed
2/14/2025, 04:02 PM
Date of event
Dec 31, 2024
SEC
View on sec.gov

Reporting Managers (10)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
BIOTECHNOLOGY VALUE FUND L P 5.3% 551K 0 551K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF I GP LLC 5.3% 551K 0 551K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BIOTECHNOLOGY VALUE FUND II LP 4.2% 432K 0 432K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF II GP LLC 4.2% 432K 0 432K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
Biotechnology Value Trading Fund OS LP 0.4% 40.6K 0 40.6K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF Partners OS Ltd. 0.4% 40.6K 0 40.6K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF GP HOLDINGS LLC 9.5% 983K 0 983K /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF PARTNERS L P/IL 9.99% 1.04M 0 1.04M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
BVF INC/IL 9.99% 1.04M 0 1.04M /s/ Mark N. Lampert Mark N. Lampert, Authorized Signatory
LAMPERT MARK N 9.99% 1.04M 0 1.04M /s/ Mark N. Lampert Mark N. Lampert